Back

Clinical outcomes and treatment response according to ATTR-CM risk in HFpEF: a real-world cohort study

29 August 2026 (10:15 - 11:00)
Organised by: Logo
Congress Presentation Part of: Heart failure: drugs, diagnosis, and demographics Heart Failure with Preserved Ejection Fraction (HFpEF) ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Cheng-En Tsai

National Taiwan University Hospital, Taipei (Taiwan)

7 More presentations in this session

Presentation thumbnail
Transcriptomic and proteomic analysis of unloaded normal hearts in rats: insights into barriers to bridge to recovery in LVAD therapy
Associate Professor Y. Shingu (Sapporo, JP)
Abstract Slides Video
Presentation thumbnail
Right ventricular myocardial stiffness assessed by non-invasive shear wave elastography in HFpEF: a pre-specified substudy of PACIFIC-PRESERVED
Professor J. Hulot (Paris, FR)
Abstract Slides Video
Presentation thumbnail
Association between echocardiographic E/e′ and invasive filling pressures at rest and exercise in transthyretin cardiac amyloidosis
Doctor T. Weiss (Aarhus, DK)
Abstract Slides Video
Presentation thumbnail
FINE-FUNCTION HF: FINErenone and FUNCTIONal capacity in heart failure after switching from spironolactone to finerenone
Mrs A. Freitas (Curitiba, BR)
Abstract Slides Video
Presentation thumbnail
Incremental benefit of sodium–glucose cotransporter 2 inhibitor and mineralocorticoid receptor antagonist therapy in HFpEF with moderate mitral regurgitation: 24-month ambulatory cohort study
Doctor V. Dimitrova (Sofia, BG)
Abstract Slides Video

Access the full session

Session thumbnail
Heart failure: drugs, diagnosis, and demographics

The Event

Event poster

ESC Congress 2026

29 August 2026 10:15 CET
You may be interested in
thumbnail
Congress Presentation
Risk prediction in ATTR-CM patients under tafamidis treatment: results from the multicentre SWISS-CARE registry
28 August 2026
thumbnail
Congress Presentation
Value of the HFA-PEFF and H2FPEF scores in patients with heart failure and preserved ejection fraction caused by cardiac amyloidosis.
27 August 2022
thumbnail
Congress Presentation
Outcomes with early access tafamidis in patients with variant transthyretin amyloid cardiomyopathy
11 May 2026
thumbnail
Congress Presentation
The incidence of death and risk factors for mortality in cardiac amyloidosis: an observational study in the UK clinical setting using electronic health records
30 August 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources